PMID- 37400762
OWN - NLM
STAT- MEDLINE
DCOM- 20230705
LR  - 20230706
IS  - 1471-2466 (Electronic)
IS  - 1471-2466 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Jul 3
TI  - Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) 
      patients with c-MET exon 14 skipping mutation, MET overexpression and 
      amplification.
PG  - 240
LID - 10.1186/s12890-023-02482-9 [doi]
LID - 240
AB  - PURPOSE: MET exon 14 skipping is one of the rare mutations in non-small cell lung 
      cancer (NSCLC), involving its pathogenesis and progression. The performances of 
      several MET inhibitors in clinical trials have been validated based on NGS, 
      immunohistochemistry (IHC), and gene copy number assessments. Thus, a detailed 
      understanding of the relationship between these markers and prognosis is 
      required. METHODS: This study has recruited patients (n = 17) with MET exon 14 
      skipping mutation and initially screened genes (n = 10) by polymerase chain 
      reaction (PCR) from 257 specimens of NSCLC, including small biopsies and surgical 
      resection. Further, the IHC analysis detected MET overexpression and recorded the 
      score using the MetMAb trial (rial ( recruited patients (n = 17) with MET 
      exstainings). Finally, the fluorescence in situ hybridization (FISH) resulted in 
      the MET amplification with a MET copy number initially screened genes (n = 10) by 
      p. RESULTS: PCR results indicated strong MET staining ( 3+) in more than 50% of 
      tumor cells. Among the recruited 17 cases of MET exon 14 skipping, 9 cases 
      presented MET amplification, and 10 cases with MET overexpression. These 
      attributes were not correlated to the clinicopathological characteristics and 
      overall survival. In addition, 4 cases showed gene amplification, and 3 cases 
      presented polyploidy condition. The correlation analysis showed a significant 
      relationship between MET amplification and MET overexpression (Pearson's 
      r2 = 0.4657, P < 0.005). CONCLUSION: Together, these findings indicated a 
      significant correlation between MET overexpression and MET amplification in NSCLC 
      patients but no correlation to prognosis.
CI  - (c) 2023. The Author(s).
FAU - Ding, Caixia
AU  - Ding C
AD  - Department of Pathology, Shaanxi Cancer Hospital, 309 Yanta West Road, Xi'an, 
      Shaanxi, 710000, China.
FAU - Qiu, Yanyi
AU  - Qiu Y
AD  - Graduate School, China Pharmaceutical University, 639 Longmian Avenue, Jiangning 
      District, Nanjing, Jiangsu, 211122, China.
FAU - Zhang, Juan
AU  - Zhang J
AD  - Department of Pathology, Shaanxi Cancer Hospital, 309 Yanta West Road, Xi'an, 
      Shaanxi, 710000, China.
FAU - Wei, Wei
AU  - Wei W
AD  - Department of Pathology, Shaanxi Cancer Hospital, 309 Yanta West Road, Xi'an, 
      Shaanxi, 710000, China.
FAU - Gao, Hongbian
AU  - Gao H
AD  - Department of Pathology, Shaanxi Cancer Hospital, 309 Yanta West Road, Xi'an, 
      Shaanxi, 710000, China.
FAU - Yuan, Yong
AU  - Yuan Y
AD  - Department of Pathology, Shaanxi Cancer Hospital, 309 Yanta West Road, Xi'an, 
      Shaanxi, 710000, China.
FAU - Wang, Xiaomin
AU  - Wang X
AD  - Department of Pathology, Shaanxi Cancer Hospital, 309 Yanta West Road, Xi'an, 
      Shaanxi, 710000, China. sfsafjga7953@126.com.
LA  - eng
GR  - S2021-YF-YBSF-0426 POXC1/Role and mechanism of POXC1 regulating PRAME to promote 
      invasion and migration of breast cancer cells/
PT  - Journal Article
DEP - 20230703
PL  - England
TA  - BMC Pulm Med
JT  - BMC pulmonary medicine
JID - 100968563
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/genetics/pathology
MH  - *Lung Neoplasms/pathology
MH  - In Situ Hybridization, Fluorescence
MH  - Proto-Oncogene Proteins c-met/genetics
MH  - Mutation
MH  - Exons/genetics
PMC - PMC10318750
COIS- The authors declare no competing interests.
EDAT- 2023/07/04 01:05
MHDA- 2023/07/05 06:42
PMCR- 2023/07/03
CRDT- 2023/07/03 23:33
PHST- 2023/01/14 00:00 [received]
PHST- 2023/05/16 00:00 [accepted]
PHST- 2023/07/05 06:42 [medline]
PHST- 2023/07/04 01:05 [pubmed]
PHST- 2023/07/03 23:33 [entrez]
PHST- 2023/07/03 00:00 [pmc-release]
AID - 10.1186/s12890-023-02482-9 [pii]
AID - 2482 [pii]
AID - 10.1186/s12890-023-02482-9 [doi]
PST - epublish
SO  - BMC Pulm Med. 2023 Jul 3;23(1):240. doi: 10.1186/s12890-023-02482-9.